Clinical trial

Intermittent Fasting, Mediterranean Diet and NAFLD

Opening soon · Not applicable · 0 countries · Registry ID NCT06615817

Opening soonNot applicableInterventional

What this study is about

This study aims to evaluate the effects of Intermittent Fasting (IF) 14/10 compared with the Low Glycemic Index Mediterranean Diet on NAFLD.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age30 Years to 65 Years

SexAll

Healthy volunteersAccepted

ConditionNAFLD, Obesity, Intermittent Fasting, Mediterranean Diet

Full registry criteria

Inclusion Criteria: * Medium/severe NAFLD (CAP\>268) * BMI between 25 and 35 Exclusion Criteria: * diabetes treated with insulin, * fatty liver disease linked to alcohol consumption, * chronic inflammatory intestinal and oncological diseases, * visceral obesity which does not allow good resolution of Fibroscan images, * subjects in serious medical conditions that may compromise participation in the trial, * people following a special diet or unable to follow a diet for religious or other reasons. * Pregnancy and breastfeeding

Treatments and study arms

Intermittent Fasting

Dietary Supplement

In this group, a diet based on intermittent fasting will be administered - with 14 hours of nocturnal fasting and 10 hours of feeding with a low glycemic index Mediterranean diet.

Primary outcomes

The effect of intervention on CAP valueat Baseline and after 4 months

To evaluate the change in hepatic steatosis score after 4 months of a low glycemic index Mediterranean diet and 14/10 intermittent fasting with a low glycemic index Mediterranean diet. The cut off to indicate the presence of steatosis is CAP\>268. A decrease in the CAP value indicates an improvement in the pathology

Study locations

0 locations were listed when this page was built. The first 40 are shown.

No public site location was included in this record. Check the original registry for updates.